Clinic Roundup

• BioDelivery Sciences International Inc., of Raleigh, N.C., said it started a confirmatory study of a formulation of buprenorphine and naloxone using BDSI's BioErodible MucoAdhesive drug delivery technology. The study will be used to select the final doses of BEMA Buprenorphine/Nalaxone to be used in the pivotal bioequivalence study compared to Suboxone set to start in January 2012.